PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.
Key facts
- Study ID
- NCT01158300
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 28
- Starts
- 2010-11-01
- Expected to finish
- 2015-01-01
- Last updated by the study team
- 2015-05-04
Who can join
Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
- Children's National Medical Center — Washington D.C., District of Columbia, United States
- Children's Memorial Hospital - Chicago — Chicago, Illinois, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.